Picton Mahoney尽管最近蒙受了财政损失,但仍在刺激Insmed生物制药公司的股权。 Picton Mahoney boosts stake in biopharm company Insmed despite its recent financial loss.

Picton Mahoney资产管理公司在Insmed公司中的股份增加了7.4%,收购了3 354个股份,共持有48 897个股份,价值337万美元。 Picton Mahoney Asset Management has increased its stake in Insmed Incorporated by 7.4%, acquiring 3,354 shares to hold a total of 48,897 shares valued at $3.37 million. 据报道, 生物制药公司Insmed的市值为13860亿美元, 每股亏损1.32美元, 比预期的1.17美元还要严重. Insmed, a biopharmaceutical company with a market cap of $13.86 billion, reported a loss of $1.32 per share, worse than the expected loss of $1.17. 其产品 " ARIKAYCE " 治疗甲状腺杆菌综合体(MAC)肺病。 Its product, ARIKAYCE®, treats Mycobacterium avium complex (MAC) lung disease.